论文部分内容阅读
为探讨BCL-2反义硫代磷酸寡脱氧核苷酸(AS-PS-ODN,ASPO)对急性原代白血病细胞和正常或良性血液病骨髓细胞的作用是否存在差别。应用台盼蓝拒染试验测定细胞存活力;用造血祖细胞集落培养:粒—单系祖细胞集落(CFU-GM),多向祖细胞集落(CFU-Mix),后红系祖细胞集落(CFU-E)、前红系祖细胞集落(BFU-E)和白血病祖细胞集落(CFU-AML,CFU-ALL)培养检测细胞增殖能力;免疫细胞化学染色检测细胞BCL-2蛋白表达变化。结果发现(1)正常或良性血液病骨髓细胞经10μmol/L ASPO处理一周,同对照组比较:细胞生长数、CFU-GM、CFU-Mix、CFU-E、BFU-E及BCL-2蛋白表达均无显著差别(P<0.05)。(2)急性原代白血病细胞经5μmol/L ASPO处理一周,同对照组比较:细胞生长数显著减低;CFU-AML或CFU-ALL显著降低(P < 0.05),而CFU-GM明显增高(P< 0.05);对照组BCL-2蛋白表达率为77.92％±22.50％,ASPO组于培养的第3天为54.05％±20.20％(P<0.01)和第6天为55.35％±22.74％(P<0.05)均显著低于对照组。因此认为BCL-2ASPO具有选择性地抑制白血病细胞的增殖和BCL-2蛋白的表达的作用。
To investigate whether BCL-2 antisense phosphorothioate oligodeoxynucleotides (AS-PS-ODN, ASPO) have different effects on acute primary leukemia cells and normal or benign hematopoietic myeloid cells. Cell viability was determined by trypan blue exclusion assay; with hematopoietic progenitor cell colonies: CFU-GM, CFU-Mix, CFU-E, BFU-E and CFU-ALL were used to detect the cell proliferation. The expression of BCL-2 protein was detected by immunocytochemical staining. The results showed that: (1) The normal and benign hematopoietic myeloid cells were treated with 10μmol / L ASPO for one week. Compared with the control group, the number of cells, CFU-GM, CFU-Mix, No significant difference (P <0.05). (2) Acute primary leukemia cells were treated with 5μmol / L ASPO for one week. Compared with the control group, the number of cell growth decreased significantly; CFU-AML or CFU-ALL significantly decreased (P < <0.05). The expression of BCL-2 protein in control group was 77.92% ± 22.50%, while in ASPO group was 54.05% ± 20.20% (P <0.01) on the third day and 55.35% ± 22.74% on the 6th day <0.05) were significantly lower than the control group. It is therefore considered that BCL-2 ASPO has the effect of selectively inhibiting the proliferation of leukemia cells and the expression of BCL-2 protein.